Ipamorelin
See our Evidence Standards for how we grade the research below.
What It Is
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the growth hormone secretagogue receptor, GHS-R1a, the same receptor ghrelin activates naturally. Activation of GHS-R1a on pituitary somatotrophs triggers a Gq-coupled signaling cascade that increases intracellular calcium and stimulates GH release. Ipamorelin was developed specifically to separate GH release from the appetite-stimulating and cortisol/prolactin-raising effects seen with earlier ghrelin mimetics such as GHRP-6, through a more selective binding profile at GHS-R1a relative to related receptors.
Because it acts on a different receptor than GHRH analogs (sermorelin, CJC-1295, tesamorelin), ipamorelin is often paired with a GHRH analog in practice on the theory that stimulating both arms of the pathway produces a larger combined GH pulse than either alone; that combination effect has limited direct human evidence and is discussed further below.
The Evidence
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998 Nov;139(5):552-61. PMID: 9849822. In vitro (primary rat pituitary cells) and in vivo (conscious swine) characterization. Ipamorelin released GH with potency and efficacy similar to GHRP-6 (ED50 2.3 nmol/kg in swine). Distinctively, ipamorelin did not raise ACTH or cortisol above baseline even at doses over 200-fold the GH-releasing dose, unlike GHRP-6 and GHRP-2 tested in the same models. Neither compound affected FSH, LH, prolactin, or TSH.
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International Journal of Colorectal Disease. 2014 Dec;29(12):1527-34. PMID: 25331030. ClinicalTrials.gov NCT00672074. Multicenter, double-blind, placebo-controlled Phase 2 trial. 117 adults undergoing bowel resection were randomized; 114 (56 ipamorelin, 58 placebo) comprised the safety/modified-intent-to-treat population. IV ipamorelin 0.03 mg/kg twice daily versus placebo, postoperative day 1 through day 7 or discharge. Ipamorelin was well tolerated at this dose and duration. There were no significant differences between ipamorelin and placebo in the primary or secondary efficacy analyses (time to first tolerated meal and related GI-recovery measures).
Note: this is the only completed human RCT of ipamorelin, and it is a short-duration (up to 7 days), IV-dosed trial in a surgical population studying GI recovery, not GH-axis outcomes. It does not establish safety or efficacy for the longer-duration, subcutaneous, self-administered use common in clinical practice, and it did not meet its own efficacy endpoint for the indication it tested.
Combined use with GHRH analogs (e.g., CJC-1295). The rationale for combining a GHRH analog with a ghrelin mimetic is mechanistically sound: the two act through different receptors and, in principle, non-redundant signaling. But mechanistic plausibility is not evidence that the combination produces a better clinical outcome than either compound alone; other physiologic factors not captured in the receptor-level reasoning could offset or fail to add to the effect in practice. A search of the published literature did not turn up a dedicated, controlled human trial testing ipamorelin combined with a GHRH analog against either compound alone; the combination's added clinical benefit remains a mechanistic argument, not a demonstrated outcome.
What's Reported in Practice
Patients and providers using ipamorelin in practice commonly report improved sleep quality, faster recovery from training or injury, and a general sense of improved wellbeing and body composition over weeks to months of use. We think these reports are worth taking seriously as a signal of where a well-designed outcomes trial could add real value, and they're consistent with what we'd mechanistically expect from a selective GH secretagogue. They have not, however, been demonstrated in a controlled human trial, so we present them as reported experience, not as established evidence.
What the Research Doesn't Yet Show
This is where we're most eager to see more research investment, not a mark against the compound. The only completed human trial of ipamorelin is a short, IV-dosed trial in surgical patients over about a week, studying GI recovery rather than GH-axis effects, and it did not meet its own efficacy endpoint. There is no published human trial of ipamorelin at the subcutaneous doses and months-long durations used in clinical practice, which is exactly the kind of trial that would let the reported benefits above be properly tested. Whether tachyphylaxis or receptor desensitization occurs with extended use has not been directly studied in humans; claims that it does not occur are extrapolated beyond what the available trial can support. The added benefit of combining ipamorelin with a GHRH analog, versus using either alone, has not been demonstrated in any controlled trial we could locate, though the underlying mechanistic rationale for trying is sound.
Compounded, not FDA-approved for this indication. Sourcing and availability are discussed at your visit.
Next Step
This page covers mechanism and evidence. Dosing, cycling, and whether this is appropriate for you are individual clinical decisions made with your provider.
Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?